EANS-News: Balda AG / Balda shareholders approve dividend payment of EUR 2.00 per share

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Annual & Special Corporate Meetings

Subtitle: - Ted Gerlach elected as new member of the supervisory
board - Plastic specialist is in advanced negotiations regarding an
acquisition in the Medical division

Bielefeld (euro adhoc) - Bielefeld, 7th November 2012 - This
Wednesday the annual general meeting of Balda AG, Bad Oeynhausen,
approved a dividend payment of EUR 2.00 per share for the short
financial year 2012 (1st January to 30th June 2012). As such a total
of around EUR 117.8 million will be distributed. The shareholders
have therefore once again participated in the proceeds arising from
the sale of the majority of the shares in the touchscreen
manufacturer TPK Holding during the short financial year. With a
presence of 60.1% of the total share capital, the shareholders
approved the proposed dividend with a substantial majority.

Additionally, the annual general meeting elected Mr Ted Gerlach as a
new supervisory board member and successor to Mr Chun-Chen Chen in
this role. Mr Gerlach is the Managing Director of BluePoint Controls
Inc. with its head office in Milpitas, California, USA. He will bring
with him his comprehensive knowledge of the North American market,
which is of growing significance to the further development of the
Balda Group. The annual general meeting also confirmed the posts of
the supervisory board members Dr. Michael Naschke and Mr Yu-Sheng
Kai. The board elected Dr. Naschke as supervisory board chairman and
Mr Gerlach as his deputy during its constituent session.

Chief Executive Officer Dominik Müser reported to the annual general
meeting on the progress of the Balda Group's reorientation during the
year 2012, principally encompassing a Buy and Build strategy for the
Balda Medical segment. The unaltered objective remains to increase
the Group's revenues in the next three years to EUR 150 to 200
million, and in doing so to increase the Medical segment revenues to
a figure considerably in excess of EUR 100 million. At the present
time Balda is in advanced negotiations regarding the acquisition of
companies in North America and Western Europe.

Dominik Müser, Chief Executive Officer of Balda AG: "We are very
confident about the future of Balda. At the beginning of this year we
found ourselves faced with many pressing tasks, the greatest part of
which we have already taking care of. This includes the
implementation of a growth strategy for Balda Medical, the
restructuring of the Electronic Products segment and the sale of the
majority of the TPK shares. Balda now has every chance of developing
into a growing, profitable midcap, one that is valued on the stock
market."

Note to the editors: The statements made by Chief Executive Officer
of Balda AG Dominik Müser at the annual general meeting can be found
on the Balda AG website (www.balda.de).

Further inquiry note:
Frank Elsner
Frank Elsner Kommunikation für Unternehmen GmbH
Tel.: +49 - 54 04 - 91 92 0
Fax: +49 - 54 04 - 91 92 29
Mail:{office@elsner-kommunikation.de}[HYPERLINK:
mailto:office@elsner-kommunikation.de]

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Balda AG
Bergkirchener Str. 228
D-32549 Bad Oeynhausen
phone: +49 (0) 5734 9 22-0
FAX: +49 (0) 5734 922-2747
mail: info@balda.de
WWW: http://www.balda.de
sector: Semiconductors & active components
ISIN: DE0005215107
indexes: CDAX, Prime All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English